Compare CALC & XWEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALC | XWEL |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 9.0M |
| IPO Year | 2020 | 2010 |
| Metric | CALC | XWEL |
|---|---|---|
| Price | $0.67 | $1.30 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 145.5K | 103.3K |
| Earning Date | 05-13-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.46 | $0.26 |
| 52 Week High | $7.20 | $2.20 |
| Indicator | CALC | XWEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 53.93 |
| Support Level | $0.50 | $1.21 |
| Resistance Level | $0.78 | $1.53 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 80.36 | 60.42 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.